688428 InnoCare Pharma
- 9.85
- -0.02-0.20%
InnoCare Pharma News
Announcement from Innocare Pharmaceuticals Co., Ltd. on the 2024 mid-year performance briefing.
InnoCare Pharma: Board of directors meeting date.
InnoCare Pharma: Monthly securities change report.
Innocare Pharmaceutical voluntarily discloses the announcement of the first dosing of ICP-332 trial subjects in the United States.
Innocare Pharmaceutical Co., Ltd.'s Announcement on Changes in Shareholders' Equity of More Than 5%
Innocare Pharmaceuticals Limited Summary of Changes in Equity Report
InnoCare Pharma: Disclosure of the financial report on the following day.
Innocare Pharmaceutical Co., Ltd.'s announcement regarding the "Improve Efficiency and Return to Increase Quality" action plan for 2024.
Innocare Pharmaceutical Co., Ltd. announcement of the first attribution period and stock listing of the 2023 Star Market Restricted Stock Incentive Plan.
InnoCare Pharma: Monthly securities change report.
InnoCare Pharma: According to the stock-based incentive plan in 2023, restricted share units were granted.
Announcement of the resolutions of the 2024 Shareholders' Annual Meeting of Innocare Pharmaceutical Co., Ltd.
Legal Opinion of Fangda Law Firm regarding the 2024 Shareholders Annual Meeting of Innocare Pharma Limited, Shanghai.
Announcement of the Board of Directors of Innocare Pharmaceutical Co., Ltd.
Innocare Pharmaceutical Co., Ltd. Announcement on using idle self-owned funds for cash management.
Announcement of innocare pharmaceutical co., LTD. on the cancellation of some unallocated restricted stocks.
Shanghai Rongzheng Enterprise Consulting Services (Group) Co., Ltd.'s independent financial advisor report on the first vesting period of Innocare Pharmaceutical Co., Ltd.'s 2023 STAR Market restricted stock incentive plan that meets the attribution conditions for the first time.
Legal Opinion of Fangda Law Firm, Shanghai regarding the Achievements of the First Vesting Period and Cancellation of Some Restricted Stocks in the 2023 Star Restricted Stock Incentive Plan of Innocare Pharmaceutical Co., Ltd.
Innocare Pharmaceuticals Co., Ltd. Announcement on the First Attribution Period of Restricted Stock Incentive Plan of the Science and Technology Innovation Board for 2023 for Partial Eligible Attribution Conditions.
Innocare Pharmaceuticals voluntarily disclosed an announcement regarding the acceptance by the National Medical Products Administration of the biological product license for tafasitamab and lenalidomide in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Analysis
Price Target
No Data
